Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Fariba Goodarzian et al.|Nature Medicine|2023Cited by 125
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G. DuBois, Araz Marachelian, Yaël P. Mossé et al.|Clinical Cancer Research|2018Cited by 88
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood CancersAdam J. Wolpaw, Yaël P. Mossé, Richard Bayliss et al.|Cancer Research|2021Cited by 70
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyRochelle Bagatell, Lisa Hang, Julie R. Park et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 47
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trialNavin Pinto, Julie R. Park, Steven G. DuBois et al.|Pediatric Blood & Cancer|2018Cited by 39